According to our (Global Info Research) latest study, the global Flumatinib Mesylate market size was valued at US$ 74.08 million in 2025 and is forecast to a readjusted size of US$ 547 million by 2032 with a CAGR of 33.5% during review period.
In 2025, global production of flumatinib mesylate reached approximately 840,000 units.Flumatinib Mesylate is an oral small-molecule BCR-ABL tyrosine kinase inhibitor (TKI), primarily used for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). It works by selectively inhibiting the kinase activity of the BCR-ABL fusion protein, thereby blocking tumor cell proliferation signaling pathways and suppressing the growth and spread of leukemic cells.
Flumatinib mesylate is characterized by strong target specificity and favorable oral bioavailability, and has certain clinical value in both first-line and second-line treatment of chronic myeloid leukemia.
Flumatinib Mesylate, as a BCR-ABL tyrosine kinase inhibitor (TKI), operates within a mature yet highly competitive segment of the chronic myeloid leukemia (CML) treatment market. With improvements in CML diagnosis and treatment as well as increasing long-term survival rates, the demand for standardized, long-term medication remains strong, providing a stable market foundation for this drug. From a competitive landscape perspective, first- and second-generation TKIs represented by Imatinib, Dasatinib, and Nilotinib have already captured the majority of the market and established a well-developed treatment paradigm. In this context, as a late-entering domestic TKI, flumatinib mesylate needs to gain market share through differentiated advantages in efficacy, safety, or tolerability, as well as through competitive pricing and reimbursement strategies. Meanwhile, national healthcare cost-control measures and volume-based procurement policies exert pricing pressure, but also help improve patient accessibility and drive market uptake. Overall, its market prospects will depend on clinical data performance, long-term safety in chronic use, and its positioning in first-line or alternative therapy, as well as its comprehensive competitiveness in pricing, distribution channels, and academic promotion.
This report is a detailed and comprehensive analysis for global Flumatinib Mesylate market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Flumatinib Mesylate market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Flumatinib Mesylate market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Flumatinib Mesylate market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Flumatinib Mesylate market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Flumatinib Mesylate
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Flumatinib Mesylate market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Jiangsu Hansoh Pharmaceutical Group, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Flumatinib Mesylate market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
200 mg/Tablet
400 mg/Tablet
Market segment by Sales Channels
Hospital
Retail pharmacy
Online
Market segment by Pharmaceutical Technology
Innovative drug
Generic drug
Market segment by Application
Chronic Myeloid Leukemia (CML)
Tyrosine Kinase Inhibitor (TKI)
Others
Major players covered
Jiangsu Hansoh Pharmaceutical Group
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Flumatinib Mesylate product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Flumatinib Mesylate, with price, sales quantity, revenue, and global market share of Flumatinib Mesylate from 2021 to 2026.
Chapter 3, the Flumatinib Mesylate competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Flumatinib Mesylate breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Flumatinib Mesylate market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Flumatinib Mesylate.
Chapter 14 and 15, to describe Flumatinib Mesylate sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Flumatinib Mesylate. Industry analysis & Market Report on Flumatinib Mesylate is a syndicated market report, published as Global Flumatinib Mesylate Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Flumatinib Mesylate market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.